News & Updates

Older adults with Alzheimer's disease who are receiving treatment with acetylcholinesterase inhibitors (AChEIs) appears to have a small reduction in the risk of age-related macular degeneration (AMD), as reported in a study.

The full analysis of the phase III COMMANDS trial continues to demonstrate the superiority of luspatercept over epoetin alfa for the treatment of erythropoiesis-stimulating agent (ESA)-naïve patients with transfusion-dependent lower-risk myelodysplastic syndromes (TD LR-MDS).

A single infusion of lovotibeglogene autotemcel (lovo-cel) resulted in near-complete resolution of vaso-occlusive events (VOEs) among patients with sickle cell disease (SCD), according to the combined analysis of phase I/II HGB-206 group C and phase III HGB-210 studies presented at ASH 2023.

Patients with metabolic dysfunction-associated steatotic liver disease (MASLD) – previously called nonalcoholic fatty liver disease (NAFLD) – but without  cirrhosis, who were treated with daily low-dose aspirin, had significant reductions in liver fat for 6 months in a new trial.

New drug applications approved by US FDA as of 16-31 December 2023 which includes New Molecular Entities (NMEs) and new biologics. It does not include Tentative Approvals. Supplemental approvals may have occurred since the original approval date.

The use of fluvoxamine for outpatient treatment of mild-to-moderate COVID-19 falls short of reducing the duration of symptoms, as shown in the ACTIV-6 study.

Neutropenia following intra-arterial chemotherapy occurs more frequently than previously reported among children with retinoblastoma, with topotecan possibly linked to a risk increase, according to a study.